US EditionBharat Biotech, GSK to cut malaria vaccine price by more than half by 2028
- Bharat Biotech International Limited and GSK will reduce the price of the RTS,S malaria vaccine to under $5 per dose by 2028, in support of Gavi, the Vaccine Alliance.
- The RTS,S vaccine is the first malaria vaccine recommended by the World Health Organisation in 2021 and has seen over 2 million vaccinations by 2023.
- Dr. Krishna Ella, Executive Chairman of Bharat Biotech, called the price drop a turning point in the global fight against malaria.
- Gavi's support aims to include the RTS,S vaccine in routine immunization programs across 12 African countries by the end of 2025.
Insights by Ground AI
Does this summary seem wrong?
15 Articles
15 Articles
All
Left
3
Center
Right
3
Hyderabad: Bharat Biotech, GSK to halve malaria vaccine price
Hyderabad: Hyderabad based vaccine manufacturer Bharat Biotech International Limited (BBIL) and global pharma major GSK have jointly pledged support to Gavi, the Vaccine Alliance, in accelerating the rollout of the world’s first malaria vaccine, RTS,S. As part of their commitment, Bharat Biotech announced that the price of the RTS,S vaccine will be reduced by more than half to under $5 per dose by 2028. This major price drop is made possible thr…
Coverage Details
Total News Sources15
Leaning Left3Leaning Right3Center0Last UpdatedBias Distribution50% Left, 50% Right
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
50% Right
L 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
